StockWatch
·
Pharmaceuticals
Board Meeting2 Nov 2026, 05:20 pm

Akums Q2 FY27: Consol PAT up 168% YoY to ₹114.6 Cr, revenue +32%, margin in guided band

AI Summary

Akums' consolidated Q2 FY27 (quarter ended 30 September 2026) revenue rose 31.9% YoY to ₹1,342.4 Cr and PAT surged 168.3% YoY to ₹114.6 Cr, with NPM expanding to 8.35% from 4.07% and OPM (EBITDA margin) to 14.51% from 9.28% a year ago — a straightforward YoY growth-cum-margin-expansion quarter, not a one-off: neither this quarter nor the year-ago quarter carried any exceptional item, so the 168% is a clean comparison. Sequentially the picture is milder — revenue +15.1% QoQ and PAT +13.5% QoQ — and OPM actually eased to 14.51% from Q1's 14.97%, so the QoQ print should be read as a continuation of an already-strong base rather than fresh acceleration; NPM similarly ticked down marginally QoQ (8.44%→8.35%). The margin story sits mainly in CDMO, the largest segment: external revenue grew 38.6% YoY to ₹1,114.9 Cr and segment result (post-depreciation) more than doubled to ₹259.0 Cr from ₹91.6 Cr, comfortably ahead of management's "high-teens volume growth" guidance from the Q1 FY27 call (value growth here is well above that bar, though volume is not separately disclosed). API, flagged for a monthly-EBITDA-breakeven target by end-FY27, narrowed its segment loss to -₹10.1 Cr from -₹18.4 Cr YoY — directionally on track — but the loss actually widened from Q1's -₹8.1 Cr, so the path isn't linear and bears watching. The reported 14.51% OPM sits inside management's reiterated 14–15% EBITDA margin target, meeting guidance, though it is off Q1's print which the company had flagged as running toward the "upper bracket." No public consensus estimate for this specific quarter turned up in a search of brokerage previews; the only available Street benchmark is a ~₹4,920 Cr FY27 full-year revenue consensus (+12.9%), against which Akums is tracking at ₹2,509 Cr for H1 FY27 — broadly consistent, not confirmable on PAT. On corporate developments, the quarter included Pure and Cure Healthcare's ₹56.0 Cr acquisition of Oriflame India's Roorkee and Noida manufacturing facilities, a stated capacity and color-cosmetics/skincare/wellness expansion move that is incremental to this quarter's P&L (deal completed during the quarter). A subsidiary separately received a ₹52.7 Cr NPPA demand notice in October, outside this result's numbers but a monitorable for the segment's liability position. Management's own press release framing — "PAT surges 168% YoY on margin expansion, revenue up 32%" — matches the reported figures without rounding discrepancies; no prior-quarter outlook from the company is contradicted by this print, and the cautiously-optimistic short-term tone from the August concall is borne out by the margin trajectory, even as Zambia's guided ~₹240 Cr H2 FY27 contribution is not yet separately visible in this segment breakout.

Key Highlights

  • Consolidated revenue ₹1,342.4 Cr (+31.9% YoY, +15.1% QoQ) and PAT ₹114.6 Cr (+168.3% YoY, +13.5% QoQ) — no exceptional items in this or either comparison quarter
  • OPM 14.51% (vs 9.28% YoY, 14.97% QoQ) within management's 14–15% EBITDA band; NPM 8.35% (vs 4.07% YoY, 8.44% QoQ)
  • CDMO, the largest segment, grew external revenue 38.6% YoY to ₹1,114.9 Cr with segment result up to ₹259.0 Cr from ₹91.6 Cr YoY — the primary growth and margin driver
  • API segment loss narrowed to -₹10.1 Cr from -₹18.4 Cr YoY (but wider than Q1's -₹8.1 Cr), tracking toward the FY27 monthly-breakeven guidance non-linearly
  • Standalone (parent-only) PAT grew a much slower 39% YoY to ₹32.6 Cr on revenue +27.7% to ₹395.0 Cr — consolidated's outsized growth is driven by subsidiaries, not the parent
  • Consolidated basic EPS ₹7.37 vs ₹6.53 (Q1 FY27) and ₹2.66 (Q2 FY26)
  • Subsidiary Pure and Cure Healthcare completed a ₹56.0 Cr acquisition of Oriflame India's Roorkee and Noida manufacturing facilities during the quarter, expanding into color cosmetics/skincare/wellness